ArticleNature communications2025

Identifying fibroblast-derived sFRP2 as a therapeutic target and engineering siRNA therapy for uterine scarring.

Juan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.